Alzheimer's Research UK UCL Drug Discovery Institute

What Alzheimer's Research UK UCL Drug Discovery Institute does

The Alzheimer's Research UK UCL Drug Discovery Institute (UCL DDI) is an academic drug discovery institute launched in 2015 and embedded within University College London's Faculty of Brain Sciences, housed in the Cruciform Building on the Bloomsbury Campus. It operates as one of three institutes in the Alzheimer's Research UK Drug Discovery Alliance, alongside sister institutes at the University of Cambridge and the University of Oxford, and is wholly funded by the charity Alzheimer's Research UK. The institute's purpose is to bridge the gap between academic neuroscience research and pharmaceutical-grade drug discovery by coupling deep disease biology expertise with industry-standard drug discovery capabilities — including target identification and validation, high-throughput screening (HTS), CRISPR screening using iPSC-derived neuronal models, phenotypic screening, medicinal chemistry, and hit-to-lead optimisation across modalities including covalent inhibitors and PROTACs.

Its core "products" are integrated drug discovery packages — validated targets, screening campaigns, medicinal chemistry optimisation, and lead molecules ready for clinical development — delivered by a multidisciplinary team of approximately nine senior scientists, including a Chief Scientific Officer with global pharma experience (Merck, GSK, Eisai, Vertex) and lead academic scientists of international standing. Its customer base is bifurcated: academic researchers across UCL, the UK, and globally submit novel targets and hypotheses for collaborative validation; pharmaceutical and biotechnology companies are solicited for ongoing or case-by-case partnerships to progress portfolio assets toward clinical development. There are no commercial pricing models; all collaboration is conducted through funded research agreements under a charitable, non-profit revenue model.

Name

Alzheimer's Research UK UCL Drug Discovery Institute

Legal name

Alzheimer's Research UK UCL Drug Discovery Institute

Website

https://ucl-ddi.alzheimersresearchuk.org

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

The Alzheimer's Research UK UCL Drug Discovery Institute is an academic drug discovery hub embedded within UCL, part of a three-institute Drug Discovery Alliance with Cambridge and Oxford. It delivers target identification, high-throughput screening, medicinal chemistry, and lead optimisation for neurodegenerative diseases to academic collaborators and pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Pharmaceutical R&D Services / Neurodegenerative Disease Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)

Keywords

• Drug discovery services
• Neurodegenerative disease research
• High-throughput screening
• Medicinal chemistry
• Target identification

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Charitable Funding: The institute is funded by Alzheimer's Research UK as part of the Drug Discovery Alliance. As an academic drug discovery institute embedded within UCL, it operates as a non-profit research organization supported by charitable funding rather than commercial revenue.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

The Alzheimer's Research UK UCL Drug Discovery Institute provides integrated, industry-standard drug discovery services that combine deep disease biology expertise with high-throughput screening, medicinal chemistry, and pharmacology to translate academic neuroscience innovations into validated drug targets and lead molecules for neurodegenerative diseases. It couples these capabilities with academic collaborations and industry partnerships to progress candidates toward clinical development.

Product overview

The Alzheimer's Research UK UCL Drug Discovery Institute is a research organization offering a unified suite of drug discovery services rather than a software product platform. The core offering comprises integrated drug discovery capabilities including target identification and validation, high-throughput screening campaigns, medicinal chemistry and lead optimization, all delivered by multidisciplinary biology, pharmacology, screening, and chemistry teams. These services are provided to academic researchers and industry partners to translate emerging neuroscience discoveries into industry-standard drug-discovery packages and lead molecules for neurodegenerative disease targets. The institute operates as part of the Alzheimer's Research UK Drug Discovery Alliance alongside institutes at Cambridge and Oxford.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Discovery Services for Neurodegenerative Diseases Integrated, industry-standard drug discovery capabilities that couple deep disease biology expertise with high-quality screening, pharmacology, and chemistry services to accelerate translation of academic innovations into new medicines for neurodegenerative diseases; offered to academic researchers and pharmaceutical/biotech partners.
• Target Identification and Validation Evaluation and validation of novel molecular targets or biological hypotheses for neurodegenerative diseases using disease expertise, CRISPR screening, iPSC-derived neuronal models, and broader academic collaborator inputs.
• High-Throughput Screening (HTS) Campaigns Functional cell-based and cell-free assay development and screening of compound libraries to identify hit compounds against validated neurodegenerative disease drug targets, including microglia model systems.
• Lead Optimization Medicinal chemistry and pharmacokinetic optimization of hit compounds into potent and selective lead compounds suitable for preclinical development, including covalent inhibitors, PROTACs, and small molecules.
• CRISPR Screening Services High-throughput CRISPR screening capabilities for target identification using iPSC-derived neuronal models in neurodegenerative disease research.
• New Industry Partnerships Collaborative drug discovery partnership framework for pharmaceutical and biotechnology companies to support portfolio development through drug discovery functions, with engagement ongoing or on a case-by-case basis depending on project needs.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Alzheimer's Research UK Drug Discovery Alliance (UCL, Cambridge, Oxford)coreStrategic or Co-development Partner · 1 January 2015The Drug Discovery Alliance is a network of Drug Discovery Institutes embedded within University College London, University of Cambridge, and University of Oxford. The Alliance accelerates discovery of novel therapeutics for Alzheimer's disease and other neurodegenerative diseases by applying industry-standard precision to emerging innovations. The three institutes create one of the largest coordinated academic drug discovery efforts, ensuring that breakthroughs by scientists go straight into the hands of drug discovery experts.
• Dementia Research Institute at UCLcoreStrategic or Co-development PartnerThe institute works very closely with scientists within the Dementia Research Institute at UCL, which serves as the Headquarters of the UK Dementia Research Institute. The Dementia Research Institute provides deep disease biology expertise and access to cutting-edge neuroscience research capabilities.
• UCL Institute of Neurology (Queen Square)coreStrategic or Co-development PartnerThe UCL DDI is part of the Faculty of Brain Sciences and the Institute of Neurology, a world centre of excellence for research into diseases of the nervous system. Access to the wealth of disease expertise at the Queens Square Institute of Neurology supports target identification and validation.
• National Hospital for Neurology & Neurosurgery, UCLH NHS Foundation TrustcoreStrategic or Co-development PartnerClose association with the National Hospital for Neurology & Neurosurgery places people at the heart of everything the institute does, connecting research to clinical practice and patient care.
• Industrial Collaborators (Pharmaceutical and Biotechnology Companies)minorStrategic or Co-development PartnerThe institute is always seeking industrial collaborators to support the development of their portfolio through a variety of drug discovery functions. Partnerships can be ongoing or on a case-by-case basis depending on the needs of particular projects.
• Global Academic CollaboratorsminorStrategic or Co-development PartnerThe institute takes a broad approach to target identification, seeking novel targets and ideas from across the UK and globally alongside partner institutes. They are interested in hearing from researchers with molecular targets or hypotheses that have potential for new therapeutic approaches for neurodegenerative diseases.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Denali Therapeutics: Clinical-stage biotech focused on neurodegeneration, leveraging deep disease biology and a broad modality toolbox (small molecules, biologics, ASOs); comparable mission of translating academic neurodegeneration science into drug candidates, but operating as a venture-backed company.

Direct peers

• Alzheimer's Research UK Cambridge Drug Discovery Institute: Sister institute in the ARUK Drug Discovery Alliance embedded at the University of Cambridge, offering identical integrated drug discovery capabilities (target ID, HTS, medicinal chemistry) for neurodegenerative diseases with comparable funding structure.
• UK Dementia Research Institute (UK DRI): Headquartered at UCL and tightly coupled with the UCL DDI; UK's national neurodegeneration research institute, focused on understanding disease mechanisms that can be translated into therapeutic targets, providing the upstream biology funnel for DDI programs.
• Alzheimer's Research UK Oxford Drug Discovery Institute: Sister institute in the ARUK Drug Discovery Alliance at the University of Oxford, providing equivalent industry-standard drug discovery services for neurodegeneration and contributing to the same coordinated pipeline as UCL.
• Stanley Center for Psychiatric Research at Broad Institute: Academic-led translational research center combining genetics, neurobiology, and chemical biology to discover therapeutics for psychiatric and neurodegenerative diseases, with very similar mission and operating model to the UCL DDI.

Broad incumbents

• Eisai (Neuroscience Business): Major pharmaceutical company with one of the largest dedicated neuroscience pipelines including lecanemab; the primary commercial partner and competitor for academic-generated neurodegeneration assets in the UK ecosystem.
• MRC Laboratory of Molecular Biology (LMB): Leading UK academic research institute producing foundational biology with biotech spin-out track record; relevant comparator for an academic institute seeking to translate basic science into therapeutic candidates, though broader in scope.
• Biogen: Established leader in neurology with aducanumab and a broad neurodegeneration pipeline; sets the bar for clinical translation that academic DDIs like UCL must meet and competes for the same pharma partnership dollars.
• Eli Lilly (Neuroscience R&D): Large pharma with major investment in Alzheimer's and neurodegeneration (donanemab, tau programs); represents the type of well-resourced industrial collaborator / competitor that the UCL DDI targets for partnerships.

Regional players

• Mayo Clinic Alzheimer's Disease Research Center: US-based academic AD research center where Sir John Hardy previously held a Chair; comparable mission of integrating disease biology with translational research, but geographically and structurally distinct.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/alzheimer-s-research-uk-ucl-drug-discovery-institute

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alzheimer's Research UK UCL Drug Discovery Institute